| Literature DB >> 33171651 |
Annalisa Quattrocchi1, Ioannis Mamais2, Constantinos Tsioutis3, Eirini Christaki4, Costas Constantinou5, Maria Koliou4, Zoi-Dorothea Pana3, Valentinos Silvestros6, Fani Theophanous6, Christos Haralambous6, Androulla Stylianou6, Sotiroula Sotiriou6, Maria Athanasiadou7, Theopisti Kyprianou7, Anna Demetriou7, Christiana A Demetriou1, Ourania Kolokotroni1, Ioanna Gregoriou6, Niki Paphitou8, George Panos4,9, Leontios Kostrikis10, Peter Karayiannis11, Georgios Petrikkos3, Petros Agathangelou12, George Mixides8, Georgios Siakallis11,13, Linos Hadjihannas5, Lakis Palazis5, Anna Vavlitou5, Chrystalla Matsentidou-Timiliotou14, Dimitris Koukios14, Tonia Adamidi5, Frangiskos Frangopoulos5, Elizabeth Constantinou6, Georgios Nikolopoulos4.
Abstract
Coronavirus disease 2019 (COVID-19) has significantly affected the well-being of individuals worldwide. We herein describe the epidemiology of COVID-19 in the Republic of Cyprus during the first epidemic wave (9 March-3 May 2020). We analyzed surveillance data from laboratory-confirmed cases, including targeted testing and population screening. Statistical analyses included logistic regression. During the surveillance period, 64,136 tests (7322.3 per 100,000) were performed, 873 COVID-19 cases were diagnosed, and 20 deaths were reported (2.3%). Health-care workers (HCWs) represented 21.4% of cases. Overall, 19.1% of cases received hospital care and 3.7% required admission to Intensive Care Units. Male sex (adjusted Odds Ratio (aOR): 3.04; 95% Confidence Interval (CI): 1.97-4.69), increasing age (aOR: 1.56; 95%CI: 1.36-1.79), symptoms at diagnosis (aOR: 6.05; 95%CI: 3.18-11.50), and underlying health conditions (aOR: 2.08; 95%CI: 1.31-3.31) were associated with hospitalization. For recovered cases, the median time from first to last second negative test was 21 days. Overall, 119 primary cases reported 616 close contacts, yielding a pooled secondary attack rate of 12% (95%CI: 9.6-14.8%). Three population-based screening projects, and two projects targeting employees and HCWs, involving 25,496 people, revealed 60 positive individuals (0.2%). Early implementation of interventions with targeted and expanded testing facilitated prompt outbreak control on the island.Entities:
Keywords: COVID-19; Cyprus; contact tracing; containment measures; pandemic; surveillance
Year: 2020 PMID: 33171651 PMCID: PMC7695263 DOI: 10.3390/jcm9113598
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Characteristics of laboratory-confirmed COVID-19 cases (n = 873) and deaths among COVID-19 cases (n = 20). Republic of Cyprus, 9 March–3 May 2020.
| Characteristics | Cases | Alive | Deaths | CFR (95%CI) | ||||
|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | |||
| Origin of infection | ||||||||
| Imported | 125 | 17.1 | 122 | 17.1 | 3 | 17.6 | 2.4 (0.5–6.9) | 1 |
| Locally acquired | 604 | 82.9 | 590 | 82.9 | 14 | 82.4 | 2.3 (1.3–3.9) | |
| Missing | 144 | 141 | 3 | |||||
| Sex | ||||||||
| Male | 437 | 50.1 | 421 | 49.4 | 16 | 80.0 | 3.7 (2.1–5.9) |
|
| Female | 436 | 49.9 | 432 | 50.6 | 4 | 20.0 | 0.9 (0.3–2.3) | |
| Age group (years) | ||||||||
| 0–9 | 27 | 3.1 | 27 | 3.2 | 0 | 0.0 | 0 |
|
| 10–19 | 34 | 3.9 | 34 | 4.0 | 0 | 0.0 | 0 | |
| 20–29 | 112 | 12.8 | 112 | 13.1 | 0 | 0.0 | 0 | |
| 30–39 | 173 | 19.8 | 173 | 20.3 | 0 | 0.0 | 0 | |
| 40–49 | 152 | 17.4 | 151 | 17.7 | 1 | 5.0 | 0.7 (0–3.6) | |
| 50–59 | 159 | 18.2 | 158 | 18.5 | 1 | 5.0 | 0.6 (0–3.5) | |
| 60–69 | 111 | 12.7 | 105 | 12.3 | 6 | 30.0 | 5.4 (2–11.4) | |
| 70–79 | 80 | 9.2 | 72 | 8.4 | 8 | 40.0 | 10 (4.4–18.8) | |
| 80+ | 25 | 2.9 | 21 | 2.5 | 4 | 20.0 | 16 (4.5–36.1) | |
| Mean ± SD (Median; (IQR)) | 46 ± 18.8 | 45 ± 18.4 | 73 ± 10.2 |
| ||||
| District | ||||||||
| Famagusta | 41 | 4.7 | 38 | 4.5 | 3 | 15.0 | 7.3 (1.5– 9.9) | 0.067 |
| Larnaca | 228 | 26.1 | 222 | 26.0 | 6 | 30.0 | 2.6 (1.0–5.6) | |
| Limassol | 97 | 11.1 | 95 | 11.1 | 2 | 10.0 | 2.1 (0.3–7.3) | |
| Nicosia | 334 | 38.3 | 331 | 38.8 | 3 | 15.0 | 0.9 (0.2–2.6) | |
| Pafos | 154 | 17.6 | 148 | 17.4 | 6 | 30.0 | 3.9 (1.4–8.3) | |
| Other (Unknown, abroad, British bases) | 19 | 2.2 | 19 | 2.2 | 0 | 0.0 | 0 | |
| Healthcare–worker | ||||||||
| No | 686 | 78.6 | 666 | 78.1 | 20 | 100.0 | 2.9 (1.8–4.5) |
|
| Yes | 187 | 21.4 | 187 | 21.9 | 0 | 0 | 0 | |
| Physician | 39 | 20.9 | 39 | 20.9 | 0 | 0 | 0 | NC |
| Nurse | 94 | 50.3 | 94 | 50.3 | 0 | 0 | 0 | NC |
| Other healthcare worker | 13 | 7 | 13 | 7 | 0 | 0 | 0 | NC |
| Auxiliary staff | 41 | 21.9 | 41 | 21.9 | 0 | 0 | 0 | NC |
| Smoking status | ||||||||
| No | 444 | 80.9 | 439 | 81.1 | 5 | 62.5 | 1.1 (0.4–2.6) | 0.183 |
| Yes | 105 | 19.1 | 102 | 18.9 | 3 | 37.5 | 2.9 (0.6 –8.1) | |
| Missing | 324 | 312 | 12 | |||||
| Symptoms at diagnosis | ||||||||
| No | 265 | 30.8 | 264 | 31.4 | 1 | 5.6 | 0.4 (0–2.1) |
|
| Yes | 594 | 69.2 | 577 | 68.6 | 17 | 94.4 | 2.9 (1.7–4.5) | |
| ≥3 symptoms | 240 | 27.9 | 234 | 27.8 | 6 | 33.3 | 2.5 (0.9–5.4) | NC |
| Cough | 303 | 51.0 | 293 | 35.2 | 10 | 58.8 | 3.3 (1.6–6.0) | NC |
| Fever | 276 | 46.5 | 268 | 32.3 | 8 | 47.1 | 2.9 (1.3–5.6) | NC |
| Sore throat | 153 | 25.8 | 151 | 18.2 | 2 | 12.5 | 1.3 (0.2–4.6) | NC |
| Myalgia | 194 | 32.7 | 191 | 23 | 3 | 18.8 | 1.6 (0.3–4.5) | NC |
| Shortness of breath/respiratory distress | 104 | 17.5 | 98 | 12 | 6 | 37.5 | 5.8 (2.1–12.1) | NC |
| Anosmia | 122 | 20.5 | 122 | 16.3 | 0 | 0 | 0 | NC |
| Diarrhea | 94 | 15.8 | 92 | 11.1 | 2 | 11.8 | 2.1 (0.3–7.5) | NC |
| Missing | 14 | 12 | 2 | |||||
| Underlying health conditions | ||||||||
| No | 450 | 58.8 | 447 | 60.0 | 3 | 15.0 | 0.7 (0–1.9) |
|
| Yes | 315 | 41.2 | 298 | 40.0 | 17 | 85.0 | 5.4 (3.2–8.5) | |
| ≥2 conditions | 98 | 12.8 | 86 | 11.5 | 12 | 60.0 | 12.2 (6.5–20.4) | NC |
| Diabetes | 68 | 8.9 | 61 | 8.2 | 7 | 35.0 | 10.3 (4.2–20.1) | NC |
| Hypertension | 124 | 16.4 | 119 | 16.1 | 5 | 25.0 | 4 (1.3–9.2) | NC |
| Heart disease (excluding Hypertension) | 61 | 8 | 52 | 7.0 | 9 | 45.0 | 14.8 (7.0–26.2) | NC |
| Chronic kidney disease | 14 | 1.9 | 9 | 1.2 | 5 | 25.0 | 35.7 (12.8–64.9) | NC |
| Chronic respiratory disease, excluding asthma | 15 | 2.2 | 12 | 1.8 | 3 | 15.0 | 20 (4.3–48.1) | NC |
| Chronic liver disease | 7 | 0.9 | 4 | 0.6 | 3 | 15.0 | 42.9 (9.9–81.6) | NC |
| Immunosuppression/HIV | 15 | 2 | 15 | 2.1 | 0 | 0.0 | 0 | NC |
| Cancer | 21 | 2.7 | 18 | 2.4 | 3 | 15.0 | 14.3 (3.0–36.3) | NC |
| Neuromuscular disorder, chronic neurological | 11 | 1.4 | 11 | 1.5 | 0 | 0.0 | 0 | NC |
| Rheumatic diseases including arthritis | 8 | 1 | 8 | 1.1 | 0 | 0.0 | 0 | NC |
| Asthma | 26 | 3.4 | 26 | 3.5 | 0 | 0.0 | 0 | NC |
| Other endocrine disorder (excluding Diabetes) | 22 | 2.9 | 22 | 3.0 | 0 | 0.0 | 0 | NC |
| Missing | 108 | 108 | 0 | |||||
| Hospitalization | ||||||||
| No | 706 | 80.9 | 706 | 82.8 | 0 | 0.0 | 0 |
|
| Yes | 167 | 19.1 | 147 | 17.2 | 20 | 100.0 | 12 (7.5–17.9) | |
| ICU admission | ||||||||
| No | 841 | 96.3 | 834 | 97.8 | 7 | 35.0 | 0.8 (0.3–1.7) |
|
| Yes | 32 | 3.7 | 19 | 2.2 | 13 | 65.0 | 40.6 (23.7–59.4) | |
| Intubation | ||||||||
| No | 846 | 96.9 | 836 | 98.0 | 10 | 50.0 | 1.2 (0.6–2.2) |
|
| Yes | 27 | 3.1 | 17 | 2.0 | 10 | 50.0 | 37.0 (19.4–57.6) | |
CFR: case-fatality ratio; CI: confidence interval; SD: standard deviation; IQR: interquartile range; NC: not calculated. * p values <0.05 are indicated in bold font.
Figure 1Number of laboratory-confirmed COVID-19-cases by date of sampling (blue), 7-day moving average by date of sampling (dash blue line), date of symptoms onset (gray), 7-day moving average by date of symptoms onset (dash gray line) and date of death (orange), and public health interventions implemented, Cyprus 1 March–3 May 2020.
Characteristics of cases by hospitalization status, and factors associated with hospitalization (univariate and multivariable analysis), Republic of Cyprus 9 March–3 May 2020 1.
| Characteristics | Hospitalized | Not Hospitalized | OR (95%CI) | aOR (95%CI) | ||
|---|---|---|---|---|---|---|
|
| % |
| % | |||
| Male | 110 | 65.9 | 327 | 46.3 |
|
|
| Age group | ||||||
| 0–9 | 4 | 2.4 | 23 | 3.3 | Ref |
|
| 10–19 | 1 | 0.6 | 33 | 4.7 | 0.2 (0.0–1.7) | |
| 20–29 | 7 | 4.2 | 105 | 14.9 | 0.4 (0.1–1.4) | |
| 30–39 | 9 | 5.4 | 164 | 23.2 | 0.3 (0.1–1.1) | |
| 40–49 | 21 | 12.6 | 131 | 18.6 | 0.9 (0.3–2.9) | |
| 50–59 | 33 | 19.8 | 126 | 17.8 | 1.5 (0.5–4.7) | |
| 60–69 | 39 | 23.4 | 72 | 10.2 |
| |
| 70–79 | 35 | 21 | 45 | 6.4 |
| |
| 80+ | 18 | 10.8 | 7 | 1 |
| |
| Smoking status (yes) | 14 | 17.5 | 91 | 19.4 | 0.9 (0.5–1.6) | NI |
| Symptoms at diagnosis (yes) | 144 | 88.9 | 450 | 64.6 |
|
|
| Cough (yes) | 90 | 57.3 | 213 | 30.8 |
| NI |
| Fever (yes) | 87 | 55.4 | 189 | 27.4 |
| NI |
| Sore throat (yes) | 26 | 16.7 | 127 | 18.5 | 0.9 (0.6–1.4) | NI |
| Myalgia (yes) | 53 | 34.2 | 141 | 20.4 |
| NI |
| Shortness of breath/respiratory distress (yes) | 45 | 29.6 | 59 | 8.7 |
| NI |
| Anosmia (yes) | 16 | 12.8 | 106 | 16.7 | 0.7 (0.4–1.3) | NI |
| Diarrhea (yes) | 21 | 13.5 | 73 | 10.6 | 1.3 (0.8–2.2) | NI |
| Underlying health conditions (yes) | 98 | 69.5 | 217 | 34.8 |
|
|
| Diabetes (yes) | 34 | 24.1 | 34 | 5.4 |
| NI |
| Hypertension (yes) | 44 | 31.4 | 80 | 12.9 |
| NI |
| Heart disease (excluding Hypertension) (yes) | 31 | 22.1 | 30 | 4.8 |
| NI |
| Chronic kidney disease (yes) | 10 | 7.2 | 4 | 0.6 |
| NI |
| Chronic respiratory disease, excluding asthma (yes) | 5 | 4.1 | 10 | 1.8 | 2.4 (0.8–7.0) | NI |
| Chronic liver disease (yes) | 5 | 3.6 | 2 | 0.3 |
| NI |
| Immunosuppression/HIV (yes) | 4 | 2.9 | 11 | 1.8 | 1.6 (0.5–5.1) | NI |
| Cancer (yes) | 9 | 6.4 | 12 | 1.9 |
| NI |
| Neuromuscular disorder, chronic neurological (yes) | 3 | 2.1 | 8 | 1.3 | 1.7 (0.4–6.4) | NI |
| Rheumatic diseases including arthritis (yes) | 0 | 0 | 8 | 1.3 | – | NI |
| Asthma (yes) | 7 | 5 | 19 | 3 | 1.7 (0.1–4.0) | NI |
| Other endocrine disorder (excluding Diabetes) (yes) | 2 | 1.4 | 20 | 3.2 | 0.4 (0.1–1.9) | |
| Death (yes) | 20 | 12 | 0 | 0 | – | NI |
OR: odds ratio; CI: confidence interval; a: adjusted; NI: not included; 1 Significant associations (p < 0.05) are indicated in bold font 2 Age group treated as continuous variable.
Figure 2Outline of testing activities, Republic of Cyprus 9 March–3 May 2020. * aggregate data reported to the Ministry of Health.
Total people screened and positive results by sex and age group—Targeted testing of employees in the public domain, in retail food and beverage services, in customer services, of the personnel of National Guard, and in nursing homes, Republic of Cyprus, 10–30 April 2020.
| Age Groups (years) | Male | Female | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Screened | Positive | Screened | Positive | Screened | Positive | ||||
|
|
| % |
|
| % |
|
| % | |
| <20 | 104 | 0 | 0.00 | 43 | 0 | 0.00 | 153 | 0 | 0.00 |
| 20–24 | 388 | 1 | 0.26 | 444 | 0 | 0.00 | 884 | 1 | 0.11 |
| 25–29 | 922 | 1 | 0.11 | 920 | 1 | 0.11 | 1953 | 2 | 0.10 |
| 30–34 | 1213 | 3 | 0.25 | 850 | 0 | 0.00 | 2179 | 3 | 0.14 |
| 35–39 | 1351 | 2 | 0.15 | 965 | 1 | 0.10 | 2423 | 3 | 0.12 |
| 40–44 | 1379 | 3 | 0.22 | 1218 | 1 | 0.08 | 2696 | 4 | 0.15 |
| 45–49 | 1374 | 1 | 0.07 | 1281 | 5 | 0.39 | 2758 | 6 | 0.22 |
| 50–54 | 1229 | 3 | 0.24 | 1202 | 1 | 0.08 | 2516 | 4 | 0.16 |
| 55–59 | 1040 | 3 | 0.29 | 937 | 2 | 0.21 | 2033 | 5 | 0.25 |
| 60–64 | 619 | 0 | 0.00 | 598 | 2 | 0.33 | 1244 | 2 | 0.16 |
| 65+ | 220 | 0 | 0.00 | 133 | 0 | 0.00 | 359 | 0 | 0.00 |
| Unknown | 906 | 0 | 0.00 | 591 | 0 | 0.00 | 1598 | 0 | 0.00 |
| Total | 10,745 | 17 | 0.16 | 9182 | 13 | 0.14 | 20,796 | 30 | 0.14 |